Amgen: We Expect To Double Biosimilar Sales By 2030
Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.
